FY2025 Earnings Forecast for PTC Therapeutics, Inc. (NASDAQ:PTCT) Issued By William Blair

PTC Therapeutics, Inc. (NASDAQ:PTCT) – Research analysts at William Blair increased their FY2025 earnings per share estimates for PTC Therapeutics in a report issued on Tuesday, October 8th. William Blair analyst S. Corwin now anticipates that the biopharmaceutical company will post earnings per share of ($5.47) for the year, up from their previous forecast of ($5.53). The consensus estimate for PTC Therapeutics’ current full-year earnings is ($5.09) per share. William Blair also issued estimates for PTC Therapeutics’ Q4 2025 earnings at ($0.95) EPS.

PTC Therapeutics (NASDAQ:PTCT) last announced its earnings results on Thursday, August 8th. The biopharmaceutical company reported ($1.16) earnings per share for the quarter, missing the consensus estimate of ($1.00) by ($0.16). The company had revenue of $186.70 million during the quarter, compared to analyst estimates of $192.12 million.

PTCT has been the subject of several other reports. Raymond James started coverage on PTC Therapeutics in a research note on Thursday. They issued a “market perform” rating for the company. Morgan Stanley increased their price objective on PTC Therapeutics from $32.00 to $45.00 and gave the stock an “equal weight” rating in a research note on Friday. Barclays increased their price objective on PTC Therapeutics from $25.00 to $31.00 and gave the stock an “equal weight” rating in a research note on Friday, August 9th. Baird R W raised PTC Therapeutics to a “strong-buy” rating in a research note on Wednesday, September 4th. Finally, UBS Group began coverage on PTC Therapeutics in a research note on Monday, August 26th. They issued a “buy” rating and a $47.00 price objective for the company. Three research analysts have rated the stock with a sell rating, five have assigned a hold rating, six have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $40.08.

PTC Therapeutics Stock Up 1.3 %

NASDAQ:PTCT opened at $39.00 on Friday. PTC Therapeutics has a 1-year low of $17.53 and a 1-year high of $41.81. The firm has a market capitalization of $2.99 billion, a price-to-earnings ratio of -5.08 and a beta of 0.65. The stock has a fifty day simple moving average of $34.59 and a 200 day simple moving average of $33.19.

Insider Activity at PTC Therapeutics

In other PTC Therapeutics news, CFO Pierre Gravier sold 2,269 shares of the firm’s stock in a transaction that occurred on Tuesday, July 16th. The stock was sold at an average price of $34.02, for a total value of $77,191.38. Following the sale, the chief financial officer now owns 53,531 shares of the company’s stock, valued at $1,821,124.62. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. 5.50% of the stock is owned by company insiders.

Institutional Trading of PTC Therapeutics

Several institutional investors have recently bought and sold shares of the stock. Allspring Global Investments Holdings LLC bought a new position in PTC Therapeutics in the 1st quarter valued at $46,000. CWM LLC raised its position in PTC Therapeutics by 354.7% in the 3rd quarter. CWM LLC now owns 2,687 shares of the biopharmaceutical company’s stock valued at $100,000 after purchasing an additional 2,096 shares during the last quarter. Quest Partners LLC bought a new position in PTC Therapeutics in the 2nd quarter valued at $128,000. Quarry LP raised its position in PTC Therapeutics by 100.0% in the 2nd quarter. Quarry LP now owns 5,000 shares of the biopharmaceutical company’s stock valued at $153,000 after purchasing an additional 2,500 shares during the last quarter. Finally, Lazard Asset Management LLC raised its position in PTC Therapeutics by 268.9% in the 1st quarter. Lazard Asset Management LLC now owns 6,504 shares of the biopharmaceutical company’s stock valued at $188,000 after purchasing an additional 4,741 shares during the last quarter.

PTC Therapeutics Company Profile

PTC Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children.